351 related articles for article (PubMed ID: 28608122)
21. Impact of lymph node ratio on survival in stage III ovarian high-grade serous cancer: a Turkish Gynecologic Oncology Group study.
Ayhan A; Ozkan NT; Sarı ME; Celik H; Dede M; Akbayır Ö; Güngördük K; Şahin H; Haberal A; Güngör T; Arvas M; Meydanlı MM
J Gynecol Oncol; 2018 Jan; 29(1):e12. PubMed ID: 29185270
[TBL] [Abstract][Full Text] [Related]
22. Evaluation of Factors Affecting Lymph Node Metastasis in Clinical Stage I-II Epithelial Ovarian Cancer.
Erdem B; Yüksel IT; Peker N; Ulukent SC; Aşıcıoğlu O; Özaydin IY; Ülker V; Akbayir O
Oncol Res Treat; 2018; 41(7-8):444-448. PubMed ID: 29975960
[TBL] [Abstract][Full Text] [Related]
23. Relevance of pelvic and para-aortic node metastases in early-stage ovarian cancer.
Bachmann C; Krämer B; Brucker SY; Stäbler A; Fend F; Wallwiener D; Grischke EM; Rothmund R
Anticancer Res; 2014 Nov; 34(11):6735-8. PubMed ID: 25368283
[TBL] [Abstract][Full Text] [Related]
24. Lymphatic mapping and sentinel node identification as related to the primary sites of lymph node metastasis in early stage ovarian cancer.
Negishi H; Takeda M; Fujimoto T; Todo Y; Ebina Y; Watari H; Yamamoto R; Minakami H; Sakuragi N
Gynecol Oncol; 2004 Jul; 94(1):161-6. PubMed ID: 15262135
[TBL] [Abstract][Full Text] [Related]
25. Does the primary route of spread have a prognostic significance in stage III non-serous epithelial ovarian cancer?
Sahin H; Meydanli MM; Sari ME; Yalcin I; Çoban G; Ozkan NT; Cuylan ZF; Erdem B; Gungorduk K; Akbayir Ö; Dede M; Salman MC; Güngör T; Ayhan A
J Ovarian Res; 2018 Mar; 11(1):21. PubMed ID: 29506569
[TBL] [Abstract][Full Text] [Related]
26. Lymph Node Involvement Pattern and Survival Differences of FIGO IIIC and FIGO IIIA1 Ovarian Cancer Patients After Primary Complete Tumor Debulking Surgery: A 10-Year Retrospective Analysis of the Tumor Bank Ovarian Cancer Network.
Gasimli K; Braicu EI; Nassir M; Richter R; Babayeva A; Chekerov R; Darb-Esfahani S; Sehouli J; Muallem MZ
Ann Surg Oncol; 2016 Apr; 23(4):1279-86. PubMed ID: 26832880
[TBL] [Abstract][Full Text] [Related]
27. Factors predictive of pelvic lymph node involvement and outcomes in melanoma patients with metastatic sentinel lymph node of the groin: A multicentre study.
Mozzillo N; Pasquali S; Santinami M; Testori A; Di Marzo M; Crispo A; Patuzzo R; Verrecchia F; Botti G; Montella M; Rossi CR; Caracò C
Eur J Surg Oncol; 2015 Jul; 41(7):823-9. PubMed ID: 25800935
[TBL] [Abstract][Full Text] [Related]
28. Staging Lymphadenectomy in Patients With Clear Cell Carcinoma of the Ovary.
Mueller JJ; Holzapfel M; Han CH; Santos K; Gunderson C; Moore K; Erickson B; Leath CA; Diaz E; Walsh C; Wethington SL; Dejbakhsh SZ; Barakat RR; Gardner GJ; Hyman DM; Soslow RA; Leitao MM
Int J Gynecol Cancer; 2016 Jan; 26(1):120-4. PubMed ID: 26509849
[TBL] [Abstract][Full Text] [Related]
29. The impact of lymph node dissection and adjuvant chemotherapy on survival: A nationwide cohort study of patients with clinical early-stage ovarian cancer.
Kleppe M; van der Aa MA; Van Gorp T; Slangen BF; Kruitwagen RF
Eur J Cancer; 2016 Oct; 66():83-90. PubMed ID: 27536891
[TBL] [Abstract][Full Text] [Related]
30. Lymph node metastasis in grossly apparent clinical stage Ia epithelial ovarian cancer: Hacettepe experience and review of literature.
Desteli GA; Gultekin M; Usubutun A; Yuce K; Ayhan A
World J Surg Oncol; 2010 Nov; 8():106. PubMed ID: 21114870
[TBL] [Abstract][Full Text] [Related]
31. Risk factors for paraaortic lymph node metastasis in endometrial cancer.
Sari ME; Yalcin İ; Sahin H; Meydanli MM; Gungor T
Int J Clin Oncol; 2017 Oct; 22(5):937-944. PubMed ID: 28523533
[TBL] [Abstract][Full Text] [Related]
32. [Treatment and prognostic analysis of ovarian cancer patients with isolated region of lymph node recurrence].
Tu H; Huang H; Huang QD; Li Z; Feng YL; Liu JH
Zhonghua Fu Chan Ke Za Zhi; 2012 Dec; 47(12):928-33. PubMed ID: 23324194
[TBL] [Abstract][Full Text] [Related]
33. Factors influencing the number of pelvic and para-aortic lymph nodes removed in surgical treatment of endometrial and ovarian cancer.
Hareyama H; Ito K; Watanabe S; Hakoyama M; Uchida A; Oku K; Watanabe Y; Hayakashi Y; Hirayama E; Okuyama K
Int J Gynecol Cancer; 2012 Nov; 22(9):1577-84. PubMed ID: 23060049
[TBL] [Abstract][Full Text] [Related]
34. Defining the optimal lymphadenectomy cut-off value in epithelial ovarian cancer staging surgery utilizing a mathematical model of validation.
Pereira A; Irishina N; Pérez-Medina T; Magrina JF; Magtibay PM; Kovaleva A; Rodríguez-Tapia A; Iglesias E
Eur J Surg Oncol; 2013 Mar; 39(3):290-6. PubMed ID: 23290581
[TBL] [Abstract][Full Text] [Related]
35. The role of staging surgery in the treatment of apparent early-stage malignant ovarian germ cell tumours.
Zhao T; Zhang H; Liu Y; Jiang H; Wang X; Lu Y
Aust N Z J Obstet Gynaecol; 2016 Aug; 56(4):398-402. PubMed ID: 27135780
[TBL] [Abstract][Full Text] [Related]
36. Prognostic value of lymph node ratio in patients with advanced epithelial ovarian cancer.
Ataseven B; Grimm C; Harter P; Prader S; Traut A; Heitz F; du Bois A
Gynecol Oncol; 2014 Dec; 135(3):435-40. PubMed ID: 25312398
[TBL] [Abstract][Full Text] [Related]
37. Pattern of lymph node metastases in clinically unilateral stage I invasive epithelial ovarian carcinomas.
Cass I; Li AJ; Runowicz CD; Fields AL; Goldberg GL; Leuchter RS; Lagasse LD; Karlan BY
Gynecol Oncol; 2001 Jan; 80(1):56-61. PubMed ID: 11136570
[TBL] [Abstract][Full Text] [Related]
38. Laparoscopic staging for apparent stage I epithelial ovarian cancer.
Melamed A; Keating NL; Clemmer JT; Bregar AJ; Wright JD; Boruta DM; Schorge JO; Del Carmen MG; Rauh-Hain JA
Am J Obstet Gynecol; 2017 Jan; 216(1):50.e1-50.e12. PubMed ID: 27567562
[TBL] [Abstract][Full Text] [Related]
39. The efficacy of systematic lymph node dissection in advanced epithelial ovarian cancer during interval debulking surgery performed after neoadjuvant chemotherapy.
Eoh KJ; Yoon JW; Lee I; Lee JY; Kim S; Kim SW; Kim YT; Nam EJ
J Surg Oncol; 2017 Sep; 116(3):329-336. PubMed ID: 28542980
[TBL] [Abstract][Full Text] [Related]
40. Extranodal extension is a powerful prognostic factor in bladder cancer patients with lymph node metastasis.
Fajkovic H; Cha EK; Jeldres C; Robinson BD; Rink M; Xylinas E; Chromecki TF; Breinl E; Svatek RS; Donner G; Tagawa ST; Tilki D; Bastian PJ; Karakiewicz PI; Volkmer BG; Novara G; Joual A; Faison T; Sonpavde G; Daneshmand S; Lotan Y; Scherr DS; Shariat SF
Eur Urol; 2013 Nov; 64(5):837-45. PubMed ID: 22877503
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
